Rani Therapeutics Holdings, Inc.
RANIHealthcare|Biotechnology|US
$0.55
+0.03 (+5.93%)
DCF Value
$0.33
Tangible Book / Share
$0.26
Cash / Share
$0.29
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06891287 An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. | Obesity | P1 | Recruiting | 60 | RCT, Double-blind | PG-102 |
| NCT05164614 Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule | Healthy Volunteers | P1 | Completed | 50 | Open-label | Forteo |
| NCT03798912 A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform | Healthy Volunteers | P1 | Completed | 62 | Open-label | — |
| NCT05890118 Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule | Healthy Volunteers | P1 | Completed | 55 | Open-label | Stelara |
| NCT04911296 Pill Swallow Study | Not Determined | N/A | Completed | 150 | Open-label | — |